Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $38.47 Consensus Target Price from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned an average rating of “Moderate Buy” from the nineteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, thirteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $38.4706.

Several research firms have recently commented on DYN. Lifesci Capital raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 14th. Cowen reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, December 8th. JPMorgan Chase & Co. decreased their target price on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, November 14th. Morgan Stanley upped their target price on shares of Dyne Therapeutics from $46.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, December 8th. Finally, Wall Street Zen downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $17.04 on Friday. The company’s fifty day moving average price is $19.67 and its 200-day moving average price is $15.35. Dyne Therapeutics has a one year low of $6.36 and a one year high of $25.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.47 and a quick ratio of 13.47. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -4.66 and a beta of 1.32.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05. On average, equities research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC bought a new position in Dyne Therapeutics during the first quarter valued at $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Dyne Therapeutics by 5.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after acquiring an additional 2,886 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Dyne Therapeutics by 58.2% in the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after acquiring an additional 366,183 shares during the period. Caxton Associates LLP bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth about $157,000. Finally, Rhumbline Advisers boosted its stake in shares of Dyne Therapeutics by 4.2% during the 1st quarter. Rhumbline Advisers now owns 133,627 shares of the company’s stock worth $1,398,000 after purchasing an additional 5,383 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.